- Endurance RP Limited is pleased to announce its commercial strategic partner Wanbang Biopharmaceutical Co., Ltd. has successfully completed the Phase 3 double-blind placebo-controlled study of. | April 17, 2023
Endurance RP: Excellent Positive Results from Phase 3 Randomised Clinical Trial of Fortacin(TM)/Senstend(TM) in China streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
acnnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from acnnewswire.com Daily Mail and Mail on Sunday newspapers.
/PRNewswire/ On November 26, 2022, Shanghai Fosun Pharma (Group) Co., Ltd.("Fosun Pharma", Stock Code: 600196.SH; 02196.HK) announced that the first batch.
Celregen Therapeutics signed a $100 million agreement to in-license China rights for a novel therapy that uses induced Pluripotent Stem Cells to repair bullous keratopathy.